Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 892 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Comparator Condition Clear all
Recruiting Phase 1 Interventional

Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

NCT07076498
View directory record Official record
Conditions
Glioma
Interventions
M032
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
36 Months and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 28, 2026, 1:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sotagliflozin Bioequivalence Study

NCT03211195
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 28, 2026, 1:27 AM EDT
Completed No phase listed Observational

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

NCT04132557
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate, Lisdexamfetamine, Atomoxetine, Amphetamine, Dextroamphetamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
430,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 28, 2026, 1:27 AM EDT
Completed Not applicable Interventional Results available

Intermittent Pneumatic Compression to Improve Revascularization Outcome

NCT04250675
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Intermittent pneumatic leg compressions, Sham
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 28, 2026, 1:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Uridine Adolescent Bipolar Depression Randomized Controlled Trial

NCT01805440
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression, Manic Depression
Interventions
Uridine, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
13 Years to 21 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 28, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

NCT03066804
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
sacubitril/valsartan, Enalapril, Valsartan, Placebo to match sacubitril/valsartan, Placebo to match enalapril, Placebo to match valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
2,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Andalusia, Alabama • Mobile, Alabama • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 28, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT00360555
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
flibanserin, flibanserin 50mg, flibanserin 100mg, placebo
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
1,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
64
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 28, 2026, 1:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics

NCT05478278
View directory record Official record
Conditions
QTc Interval, Pharmacokinetics
Interventions
Psilocybin, Moxifloxacin, Micro-Crystalline Cellulose
Drug
Lead sponsor
Usona Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 28, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional Results available

Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease

NCT02730793
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Oral Aztreonam, Nasal Aztreonam, Nasal Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
7 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 28, 2026, 1:27 AM EDT
Recruiting Not applicable Interventional

Implementing Contingency Management for Stimulant Use in Specialty Addiction Treatment Organizations

NCT05702021
View directory record Official record
Conditions
Stimulant Use (Diagnosis)
Interventions
Science to Service Laboratory
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Chicago, Illinois • Rockford, Illinois • Pawtucket, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 28, 2026, 1:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions

NCT00865852
View directory record Official record
Conditions
Healthy
Interventions
Metformin HCl 750 mg Extender Release tablets, single dose, GLUCOPHAGE® XR 750 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 28, 2026, 1:27 AM EDT
Not yet recruiting Phase 2 Interventional

Daridorexant for People With Insomnia and Alcohol Use Disorder Study

NCT07701928
View directory record Official record
Conditions
Alcohol Use Disorder, Insomnia
Interventions
Daridorexant, Placebo, Brief Counseling, MEMS and Medication Accounting, Contingency Management for Medication Adherence
Drug · Behavioral · Device
Lead sponsor
Sterling McPherson
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 28, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional Results available

Adherence to Antidepressant Treatment in Subjects With Depression

NCT03388164
View directory record Official record
Conditions
Depression
Interventions
Escitalopram + RT2CK17, Escitalopram + Placebo
Drug
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 28, 2026, 1:27 AM EDT
Completed Phase 2Phase 3 Interventional

Dasotraline Binge Eating Disorder Study

NCT02564588
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Dasotraline, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
43
States / cities
Beverly Hills, California • Encino, California • Garden Grove, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 28, 2026, 1:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

Mindfulness Meditation for Insomnia

NCT06972303
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Insomnia, Insomnia Chronic, Mindfulness, Telemedicine
Interventions
Instructed bedtime app-guided mindfulness meditation, Uninstructed app-guided mindfulness meditation, Sleep hygiene education
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 28, 2026, 1:27 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Tdap and Biomarkers of Alzheimer's Disease

NCT05183516
View directory record Official record
Conditions
Alzheimer Disease, Late Onset
Interventions
tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
Biological
Lead sponsor
Mindful Diagnostics and Therapeutics, LLC
Industry
Eligibility
50 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Eau Claire, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 28, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

NCT00221403
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperidone oral solution, Valproate Oral Solution, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 7 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 28, 2026, 1:27 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Transformative Research in Diabetic Nephropathy 2.0

NCT07444203
View directory record Official record
Conditions
Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 28, 2026, 1:27 AM EDT
Recruiting Not applicable Interventional

Advancing Diabetes Management for People With Physical Disabilities Optimally Through Primary Care-Based Telehealth (ADDOPT)

NCT07032844
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Digital Health Coaching, Continuous Glucose Monitoring Teleconsults
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 1:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Non-fasting Conditions

NCT00864734
View directory record Official record
Conditions
Healthy
Interventions
Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 28, 2026, 1:27 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Pork Protein on Recovery Following Simulated Fireground Activity

NCT07819565
View directory record Official record
Conditions
Exercise Recovery, Physical Performance Parameters, Muscle Damage, Cognition, Blood Biomarkers, Stress
Interventions
Pork-Based Protein Ready-to-Eat Meals, Plant-Based Protein Ready-to-Eat Meals, Carbohydrate-Focused Lower-Protein Ready-to-Eat Meals
Other
Lead sponsor
Sam Houston State University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Fort Worth, Texas • Huntsville, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 28, 2026, 1:27 AM EDT
Completed Not applicable Interventional

Attention Training for Underserved Youth With Anxiety

NCT03028792
View directory record Official record
Conditions
Anxiety
Interventions
Attention Modification Program, Attention Control Condition
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
8 Years to 17 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
El Centro, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 28, 2026, 1:27 AM EDT
Recruiting Phase 3 Interventional

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

NCT06136559
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Nemtabrutinib, Ibrutinib, Acalabrutinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
49
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 1:27 AM EDT
Recruiting Not applicable Interventional

Targeted TDCS to Enhance Speech-Language Treatment Outcome in Persons With Chronic Post-Stroke Aphasia.

NCT04432883
View directory record Official record
Conditions
Stroke, Aphasia
Interventions
Active Comparator: Experimental: Active cathodal tDCS + language training, Sham Comparator: Placebo cathodal tDCS + Speech and language
Device · Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
25 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 28, 2026, 1:27 AM EDT